跳至主要内容
临床试验/NCT02881112
NCT02881112已完成不适用

An Open-Label, Non-Controlled Study to Evaluate Outcomes of Pulsed Electromagnetic Field (PEMF) Therapy in Subjects With Various Pain Etiologies

Regenesis Biomedical, Inc.16 个研究点 分布在 1 个国家目标入组 180 人开始时间: 2016年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
180
试验地点
16
主要终点
Pain Intensity Assessment

研究概览

简要总结

The study is an open-label, non-controlled study of the safety and effectiveness of investigator determined Provant therapy in subjects with pain and/or edema from various pain etiologies. Information collected in the study will be entered into a registry database.

详细描述

This is an open-label, non-controlled trial in subjects with various pain etiologies at multiple centers in the US. Eligible subjects will include those ≥ 22 years of age that have been deemed appropriate for treatment with Provant by the study investigator (prescriber). Subjects will treat based on the treatment prescribed (location, frequency, duration) by the study investigator.

Data from assessments administered as part of standard of practice will be obtained at baseline and, at a minimum, at the end of treatment. If the investigator administers additional assessments during the course of treatment, the data will be collected.

Safety will be assessed during office visits and through review of AE reports and concomitant treatments and medications. All concomitant drug or non-drug treatments used during the study will be recorded.

Information collected in the study will be entered into a registry database.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
22 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subject age is greater than or equal to 22 years.
  • Subject has pain (chronic or acute) and/or edema that the prescriber deems treatment with Provant is warranted.
  • Subject is willing and able to give written informed consent.
  • Female subjects must be post-menopausal, surgically sterile, abstinent, or practicing (or agree to practice) an effective method of birth control if they are sexually active for the duration of the study. (Effective methods of birth control include prescription hormonal contraceptives, intrauterine devices, double-barrier methods, and/or male partner sterilization).

排除标准

  • Subject requires or anticipates the need for surgery of any type during the duration of treatment.
  • Subject has received any investigational drug or device within 30 days or 5 half-lives of the drug, whichever is longer, prior to the Screening Visit or is enrolled in another clinical trial.
  • Subject has used systemic corticosteroids within 2 months of the Screening Visit.
  • Subject has a history of a solid tumor that is not in complete remission for greater than 2 years other than successfully treated non-metastatic basal cell or squamous cell carcinomas of the skin in the treatment area.
  • Subject has a history of blood cancer (e.g., leukemia, lymphoma, multiple myeloma).
  • Subject has a serious psychosocial co-morbidity.
  • Subject has a history of drug or alcohol abuse within one year prior to the Screening Visit.
  • Subject has an implanted pacemaker, defibrillator, neurostimulator, spinal cord stimulator, bone stimulator, cochlear implant, or other implanted device with an implanted metal lead(s).
  • Subject is currently pregnant or planning on becoming pregnant during the treatment period.
  • Subject has been previously treated with the Provant Therapy System.
  • Subject is unwilling or unable to follow study instructions, or comply with the treatment regimen and study visits.

结局指标

主要结局

Pain Intensity Assessment

时间窗: Pain scores collected daily, up to 20 weeks.

Change in Pain from Baseline/Pre-treatment to End of Treatment/Last Available Observation. Pain captured using NPRS, 0-10 scale were 0 = no pain and 10 = worst pain, given to subjects as part of a daily diary.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (16)

Loading locations...

相似试验

进行中(未招募)
不适用
An open label study to evaluate the efficacy, safety and tolerability of RWJ333369 as adjunctive therapy in subjects with partial onset seizurePartial Onset Epilepsy Seizures
EUCTR2007-001801-99-HUJanssen-Cilag International N.V.510
已完成
1 期
Admiral: a study of the safety of multiple increasing doses of STK-001 in children and adolescents with Dravet syndromeDravet syndromeNervous System DiseasesEpilepsy
ISRCTN99651026Stoke Therapeutics, Inc19
招募中
3 期
A safety and efficacy study of GWP42003-P oral solution as adjunctive treatment for Japanese children and adults with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complexennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex
JPRN-jRCT2031220041Yamamoto Tomoyuki84
进行中(未招募)
1 期
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or without Dasabuvir and with Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults with Successfully Treated Early Stage Hepatocellular Carcinoma
EUCTR2015-001049-10-ESAbbVie Deutschland GmbH & Co. KG3
进行中(未招募)
1 期
An open-label study to evaluate the safety and efficacy of IMATINIB with chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL)Children and adolescents aged 1-17 years at diagnosis, with Ph+ALLMedDRA version: 14.1Level: LLTClassification code 10000844Term: Acute lymphoblastic leukaemiaSystem Organ Class: 100000004864
EUCTR2004-001647-30-ITA.I.E.O.P. - ASSOCIAZIONE ITALIANA EMATOLOGIA ONCOLOGIA PEDIATRICA550
A Registry Study to Evaluate Outcomes of PEMF... | 临床试验